155 related articles for article (PubMed ID: 10619499)
1. A phase I study of high-dose BCNU, etoposide and escalating-dose thiotepa (BTE) with hematopoietic progenitor cell support in adults with recurrent and high-risk brain tumors.
Papadopoulos KP; Balmaceda C; Fetell M; Kaufman E; Vahdat LT; Bruce J; Sisti M; Isaacson S; De LaPaz R; Savage DG; Troxel A; Antman KH; Hesdorffer CS
J Neurooncol; 1999 Sep; 44(2):155-62. PubMed ID: 10619499
[TBL] [Abstract][Full Text] [Related]
2. High-dose thiotepa and etoposide-based regimens with autologous hematopoietic support for high-risk or recurrent CNS tumors in children and adults.
Papadopoulos KP; Garvin JH; Fetell M; Vahdat LT; Garrett TJ; Savage DG; Balmaceda C; Bruce J; Sisti M; Isaacson S; De LaPaz R; Hawks R; Bagiella E; Antman KH; Hesdorffer CS
Bone Marrow Transplant; 1998 Oct; 22(7):661-7. PubMed ID: 9818693
[TBL] [Abstract][Full Text] [Related]
3. CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer.
Papadopoulos KP; Ayello J; Reiss RF; Troxel A; Kaufman E; Vahdat LT; Antman KH; Hesdorffer CS
J Hematother Stem Cell Res; 1999 Aug; 8(4):357-63. PubMed ID: 10634173
[TBL] [Abstract][Full Text] [Related]
4. Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group.
Finlay JL; Goldman S; Wong MC; Cairo M; Garvin J; August C; Cohen BH; Stanley P; Zimmerman RA; Bostrom B; Geyer JR; Harris RE; Sanders J; Yates AJ; Boyett JM; Packer RJ
J Clin Oncol; 1996 Sep; 14(9):2495-503. PubMed ID: 8823328
[TBL] [Abstract][Full Text] [Related]
5. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
[TBL] [Abstract][Full Text] [Related]
6. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
[TBL] [Abstract][Full Text] [Related]
7. A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies.
Demirer T; Ilhan O; Mandel NM; Arat M; Günel N; Celebi H; Ustün C; Akan H; Demirer S; Aydintuğ S; Uysal A; Koç H
Bone Marrow Transplant; 2000 Apr; 25(7):697-703. PubMed ID: 10745253
[TBL] [Abstract][Full Text] [Related]
8. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
9. [High dose chemotherapy with thiotepa, carboplatin, VP16 and autologous stem cell transplantation in treatment of malignant brain tumors with poor prognosis. Results of a mono-center pilot study].
Fleischhack G; Pöpping K; Hasan C; Utsch B; Jüttner J; Bode U
Klin Padiatr; 1998; 210(4):248-55. PubMed ID: 9743961
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of high-dose thiotepa with busulfan, etoposide, and autologous stem cell support in children with disseminated solid tumors.
Pession A; Prete A; Locatelli F; Bella S; Melchionda F; Garaventa A; Burnelli R; Paolucci G
Med Pediatr Oncol; 1999 Nov; 33(5):450-4. PubMed ID: 10531568
[TBL] [Abstract][Full Text] [Related]
11. Regimen-related toxicity of myeloablative chemotherapy with BCNU, thiotepa, and etoposide followed by autologous stem cell rescue for children with newly diagnosed glioblastoma multiforme: report from the Children's Cancer Group.
Grovas AC; Boyett JM; Lindsley K; Rosenblum M; Yates AJ; Finlay JL
Med Pediatr Oncol; 1999 Aug; 33(2):83-7. PubMed ID: 10398181
[TBL] [Abstract][Full Text] [Related]
12. Etoposide-containing regimens with autologous bone marrow transplantation in children with malignant brain tumors.
Busca A; Miniero R; Besenzon L; Cordero di Montezemolo L; Cenni M; Fagioli F; Sandri A; Vassallo E; Ricardi U; Madon E
Childs Nerv Syst; 1997; 13(11-12):572-7. PubMed ID: 9454971
[TBL] [Abstract][Full Text] [Related]
13. High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system.
Gill P; Litzow M; Buckner J; Arndt C; Moynihan T; Christianson T; Ansell S; Galanis E
Cancer; 2008 Apr; 112(8):1805-11. PubMed ID: 18300237
[TBL] [Abstract][Full Text] [Related]
14. Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies.
Long GD; Negrin RS; Hoyle CF; Kusnierz-Glaz CR; Schriber JR; Blume KG; Chao NJ
Cancer; 1995 Sep; 76(5):860-8. PubMed ID: 8625190
[TBL] [Abstract][Full Text] [Related]
15. High-dose thiotepa and etoposide in children with poor-prognosis brain tumors.
Fagioli F; Biasin E; Mastrodicasa L; Sandri A; Ferrero I; Berger M; Vassallo E; Madon E
Cancer; 2004 May; 100(10):2215-21. PubMed ID: 15139067
[TBL] [Abstract][Full Text] [Related]
16. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer.
Bitran JD; Samuels B; Klein L; Hanauer S; Johnson L; Martinec J; Harris E; Kempler J; White W
Bone Marrow Transplant; 1996 Feb; 17(2):157-62. PubMed ID: 8640160
[TBL] [Abstract][Full Text] [Related]
17. High dose chemotherapy with autologous bone marrow rescue for children with diffuse pontine brain stem tumors. Children's Cancer Group.
Dunkel IJ; Garvin JH; Goldman S; Ettinger LJ; Kaplan AM; Cairo M; Li H; Boyett JM; Finlay JL
J Neurooncol; 1998 Mar; 37(1):67-73. PubMed ID: 9525840
[TBL] [Abstract][Full Text] [Related]
18. Mobilized peripheral blood progenitor cells (PBPC) in support of tandem cycles of high-dose chemotherapy (HDC).
Meisenberg BR; Miller WE; McMillan R
Bone Marrow Transplant; 1996 Dec; 18(6):1087-93. PubMed ID: 8971377
[TBL] [Abstract][Full Text] [Related]
19. High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumors.
Papadakis V; Dunkel IJ; Cramer LD; Kramer E; Papadopoulos E; Goldman S; Packer RJ; Willoughby M; Baker D; Garvin J; Strandjord S; Coccia P; Kaplan AM; Klemperer M; Finlay JL
Bone Marrow Transplant; 2000 Jul; 26(2):153-60. PubMed ID: 10918425
[TBL] [Abstract][Full Text] [Related]
20. A pilot trial of tandem autologous peripheral blood progenitor cell transplantation following high-dose thiotepa and carboplatin in children with poor-risk central nervous system tumors.
Ozkaynak MF; Sandoval C; Levendoglu-Tugal O; Jayabose S
Pediatr Hematol Oncol; 2004; 21(7):635-45. PubMed ID: 15626020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
